Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) is scheduled to release its earnings data on Tuesday, May 6th. Persons interested in registering for the company’s earnings conference call can do so using this link.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Monday, February 10th. The company reported ($0.59) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.45) by $0.14. The company had revenue of $12.80 million for the quarter, compared to the consensus estimate of $8.50 million. During the same quarter last year, the company posted ($0.35) earnings per share. Momenta Pharmaceuticals’s revenue was up .8% compared to the same quarter last year. On average, analysts expect Momenta Pharmaceuticals to post $0.40 EPS for the current fiscal year and $2.15 EPS for the next fiscal year.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 11.14 on Monday. Momenta Pharmaceuticals has a 52 week low of $10.24 and a 52 week high of $19.90. The stock has a 50-day moving average of $12.3 and a 200-day moving average of $16.04. The company’s market cap is $570.6 million.

On a related note, analysts at TheStreet downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 5th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.80.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.